Tempus Expands Next Platform to Deliver Real-Time Clinical Intelligence and Close Critical Care Gaps Across Oncology
Stocks in this Quantisnow insightTechnology
Historical context for TEM
Across the 25 sessions after earlier TEM headlines, the stock closed higher 14 times and lower 11 times, with a median move of 3.2% in either direction. This shows timing only: many things move a stock in a session, and these figures do not show that any headline caused a move.
| Session | Earlier headline | TEM | SPY |
|---|---|---|---|
| May 27, 2026 | Tempus Upgrades Its Smart Physician Platform, Hub, with Next-Generation Agentic AI Architecture to Streamline Clinical Workflows | +1.1% | -0.0% |
| May 26, 2026 | Tempus Announces 37 Abstracts Accepted for Presentation at the 2026 American Society of Clinical Oncology Annual Meeting | +1.0% | +0.7% |
| May 21, 2026 | Tempus Launches ArteraAI Prostate Test for Metastatic Patients, Marking the First Prostate Digital Pathology Algorithm in the Tempus Ecosystem Available for Clinical Use | +1.3% | +0.2% |
| May 11, 2026 | Ambry Genetics' CARE Program® Wins 2026 MedTech Breakthrough Award for "Best Overall Health Informatics Solution" | -2.8% | +0.2% |
| May 8, 2026 | Tempus Announces Pricing of Upsized Offering of $400.0 Million of Convertible Senior Notes | +0.8% | +0.8% |
| May 7, 2026 | Tempus AI, Inc. Announces Proposed Convertible Senior Notes Offering to Optimize Capital Structure and Reduce Interest Expense | -7.5% | -0.3% |
Quantisnow market dataNASDAQ
TEM
Tempus AI Inc.
- Market cap
- 30-day
- Sector
- Technology
- Industry
- Computer Software: Programming Data Processing
- Listed since
- 2024
Get push alerts for TEM
Full TEM profile on Quantisnow Follow TEM and get a push notification the moment its next story breaks.